FOLH1 and neoplasm: Several studies have shown the utility of PSMA in the imaging of renal function [25,26,27,28]; therefore, we hypothesised that 68Ga-PSMA PET/CT imaging could be used as a surrogate for the determination of PSMA-PETderived split renal function (SRF) at baseline, to assess kidney function and detect changes during follow-up, and to rule out obstruction induced by tumour or renal dysfunction caused by PSMA-targeted radioligand treatment.